Literature DB >> 15184056

T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene.

Maria A Burnatowska-Hledin1, Jennifer B Kossoris, Christa J Van Dort, Rebecca L Shearer, Ping Zhao, Douglas A Murrey, Jessica L Abbott, Charlene E Kan, Christopher C Barney.   

Abstract

Vasopressin-activated calcium-mobilizing (VACM-1), a cul-5 gene, is localized on chromosome 11q22-23 close to the gene for Ataxia Telangiectasia in a region associated with a loss of heterozygosity in breast cancer tumor samples. To examine the biological role of VACM-1, we studied the effect of VACM-1 expression on cellular growth and gene expression in T47D breast cancer cells. Immunocytochemistry studies demonstrated that VACM-1 was expressed in 0.6-6% of the T47D cells and localized to the nucleus of mitotic cells. Overexpressing VACM-1 significantly attenuated cellular proliferation and MAPK phosphorylation when compared to the control cells. In addition, VACM-1 decreased egr-1 and increased Fas-L mRNA levels. Further, egr-1 protein levels were significantly lower in the nuclear fraction from VACM-1 transfected cells when compared to controls. These data indicate that VACM-1 is involved in the regulation of cellular growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184056     DOI: 10.1016/j.bbrc.2004.05.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Authors:  Tomoaki Tanaka; Tatsuya Nakatani; Tetsu Kamitani
Journal:  Mol Oncol       Date:  2012-01-21       Impact factor: 6.603

Review 2.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.

Authors:  Wen Zhou; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

Review 3.  Friend or foe, the role of EGR-1 in cancer.

Authors:  Tong-Tong Li; Man-Ru Liu; Dong-Sheng Pei
Journal:  Med Oncol       Date:  2019-11-20       Impact factor: 3.064

Review 4.  The functions and properties of cullin-5, a potential therapeutic target for cancers.

Authors:  Feng Gao; Yimin Fan; Bolun Zhou; Weihua Guo; Xingjun Jiang; Jing Shi; Caiping Ren
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

5.  Mammalian Elongin A complex mediates DNA-damage-induced ubiquitylation and degradation of Rpb1.

Authors:  Takashi Yasukawa; Takumi Kamura; Shigetaka Kitajima; Ronald C Conaway; Joan W Conaway; Teijiro Aso
Journal:  EMBO J       Date:  2008-11-27       Impact factor: 11.598

6.  Granulocytic differentiation of HL-60 promyelocytic leukemia cells is associated with increased expression of Cul5.

Authors:  Shaneen S Baxter; Lauren A Carlson; Alejandro M S Mayer; Mary L Hall; Michael J Fay
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-01-01       Impact factor: 2.416

7.  Phosphorylation of VACM-1/Cul5 by protein kinase A regulates its neddylation and antiproliferative effect.

Authors:  Shirley E Bradley; Alyssa E Johnson; Isabelle P Le; Elizabeth Oosterhouse; Michael P Hledin; Gabriel A Marquez; Maria Burnatowska-Hledin
Journal:  J Biol Chem       Date:  2009-11-16       Impact factor: 5.157

8.  E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.

Authors:  Rahul S Samant; Paul A Clarke; Paul Workman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-23       Impact factor: 11.205

9.  Estrogen-dependent growth and estrogen receptor (ER)-alpha concentration in T47D breast cancer cells are inhibited by VACM-1, a cul 5 gene.

Authors:  Alyssa E Johnson; Isabelle P Le; Abby Buchwalter; Maria A Burnatowska-Hledin
Journal:  Mol Cell Biochem       Date:  2006-12-22       Impact factor: 3.842

Review 10.  The role of cullin 5-containing ubiquitin ligases.

Authors:  Fumihiko Okumura; Akiko Joo-Okumura; Kunio Nakatsukasa; Takumi Kamura
Journal:  Cell Div       Date:  2016-03-09       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.